Agilent Q4: Expecting Market Recovery In 2025
Portfolio Pulse from
Agilent Technologies, Inc. is expected to see market recovery by 2025, with a 'Buy' rating and a target price of $150. The acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics. FY25 guidance includes core revenue growth of 2.5%-3.5% and adjusted EPS growth of 5.8%.
November 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agilent Technologies is rated 'Buy' with a target price of $150, driven by strategic growth and market recovery. The acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics.
The 'Buy' rating and target price of $150 suggest positive investor sentiment. The acquisition of BIOVECTRA is expected to enhance Agilent's CDMO business, which is a strategic growth area. The FY25 guidance aligns with market expectations, supporting the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100